Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Included In Small-Cell Lung Cancer Guidelines In US For Second-Line Use
Executive Summary
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
You may also be interested in...
Pivotal Year Ahead For Spain's PharmaMar
The Madrid-based group's Aplidin is set to go back yet again to European regulators but the sea squirt-derived drug seems to be showing more potential in COVID-19 than in multiple myeloma.
Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.